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cloning, sequencing and relative semi-quantification to describe naturally occurringBRCA1alternative splicing
with unprecedented resolution. The study has been conducted in blood-related RNA sources, commonly used
for clinical splicing assays, as well as in one healthy breast tissue. We have characterized a total of 63 BRCA1
alternative splicing events, including 35 novel findings. A minimum of 10 splicing events (D1Aq, D5, D5q, D8p,
D9,D(9,10),D9_11,D11q,D13p andD14p) represent a substantial fraction of the full-length expression level (ran-
gingfrom5to100%).Remarkably,ourdata indicate thatBRCA1alternativesplicing issimilar inbloodandbreast,
a finding supporting the clinical relevance of blood-based in vitro splicing assays. Overall, our data suggest
an alternative splicing model in which most non-mutually exclusive alternative splicing events are randomly
combined into individual mRNA molecules to produce hundreds of different BRCA1 isoforms.
INTRODUCTION
Virtually all human multiexon loci are subject to alternative spli-
cing (1–4), a biological process that can produce multiple
mature RNA transcripts (RNA isoforms) from a single locus
(2,5). Alternative splicing is believed to occur in all metazoan
organisms, but it is more prevalent in vertebrates (in particular
birds and mammals), thus suggesting a link with phenotypic
complexity (6,7). However, the adaptive role of this mechanism
remains elusive (8), in part because the function of many splicing
isoforms is unclear (4). Indeed, many of them lack annotated
coding sequences (CDSs) (9), or introduce premature termin-
ation codons (PTCs) that are predicted to induce the nonsense-
mediated mRNA decay (NMD) pathway (10). In this regard, it
has been suggested that alternative splicing not only increases
the complexity of transcriptomes and proteomes but also plays
a significant role in gene regulation (8,11). However, it has
also been proposed that many alternative splicing events do
not have functional significance at all, but rather represent sto-
chastic noise in the splicing process (12).
The breast cancer predisposing gene BRCA1 (MIM# 113705)
was identified in 1994 by positional cloning in families with mul-
tiple cases of breast and ovarian cancer (13). The full-length
BRCA1 transcript includes 23 exons (22 coding exons) that
encode a 1863 amino acid protein involved in multiple DNA
repair pathways and cell-cycle checkpoint regulation (14). In
addition to mRNA aberrations arising as a consequence of patho-
genic germline mutations associated with high risk of cancer
(15), several BRCA1 alternative splicing isoforms have been
described in the literature (13,16–27). Some of them, in particu-
lar those detected solely in tumor samples and/or cell lines
(16,20,22), probably represent aberrant by-products of (or
somatic alteration contributing to) tumorigenesis. However,
others certainly represent ‘naturally occurring’ splicing iso-
forms, here defined as alternative splicing isoforms produced
by wild-type alleles in non-malignant tissues. For instance,
D(9,10), D11q and D(9,10,11q) have been described (together
with the full length) as ‘predominant’ isoforms expressed in a
wide variety of tissues (16,28). More recently, six BRCA1 tran-
scripts (D5, D5q, D8p, D(9,10), D13p and D14p) have been
reported to be ‘consistently found in control samples’ (29).
The most comprehensive review published so far describes up
to 21BRCA1 alternative splicing isoforms, albeit not all formally
validated as ‘naturally occurring’ isoforms (16).
According to several reports, the relative expression levels of
D(9,10), D11q and D(9,10,11q) are tissue specific, cell-cycle
regulated and markedly altered in tumor samples, albeit
conflicting results have been published (16). These observations
suggest thatBRCA1alternativesplicingcouldplaya role incertain
cellular functions and might be involved in carcinogenesis (16).
The D11q and D(9,10,11q) isoforms are remarkable in that they
lack .50% of the full-length CDS, suggesting that the encoded
proteins greatly differ from the full length in their biological activ-
ities. Apparently, engineered mice models supported specific
roles forD11 (mice donotexpressD11q) during early embryogen-
esis (30–33). However, the later discovery of BRCA1-IRIS (18),
a BRCA1 locus product containing an open reading frame that
extends from full-length start codon in exon 2 to the end of exon
11, continuing for 34 more triplets into intron 11 where it termi-
nates, complicated the interpretation of previous data derived
from mice models (28). Interestingly, mounting evidence indi-
cates that BRCA1-IRIS, contrary to BRCA1 full length, has
oncogenic-like activity (34). Despite these and other efforts, the
physiological and pathological roles (if any) ofBRCA1alternative
splicing remain to be established.
An accurate description of ‘naturally occurring’ alternative
splicing at the BRCA1 locus is a prerequisite to understand its
biological significance. In addition, it will become a valuable re-
source for the design and interpretation of in vitro splicing assays
conducted to investigate the pathogenicity of germline genetic
variants (15,26,35–37). To date, a systematic analysis of alter-
native splicing at the BRCA1 locus is yet to be conducted.
Here, we report a collaborative effort of the Evidence-based
Network for the Interpretation of Germ-line Mutant Alleles
(ENIGMA) consortium (38) conducted to comprehensively
analyze BRCA1 alternative splicing events occurring in four
blood-related RNA sources, commonly used for clinical splicing
assays, and one healthy breast tissue.
RESULTS
After conducting a four-stage project (Fig. 1), we have been able
to annotate 63 independent BRCA1 alternative splicing events
(Tables 1–4) and Supplementary Material, Table S1), including
46 fully characterized by sequencing of the spliced junctions and
17 imputed from capillary electrophoresis (CE) alternative spli-
cing models (Supplementary Material, Fig. S1–S3). Out of 63
events, 61 were observed in lymphoblastoid cell lines (LCLs),
53 in primary cultures of stimulated peripheral blood leukocytes
(PBLs), 51 in whole blood leukocytes (LEUs), and 46 in
ficoll-isolated peripheral blood mononuclear cells (PBMCs)
(Supplementary Material, Table S2). The overlap was signifi-
cant, with 39 events (62%) detected in all four RNA sources,
Human Molecular Genetics, 2014, Vol. 23, No. 14 3667
 at JISC - England and Scotland on July 16, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
and 51 events (81%) detected in at least three of them. Most dis-
crepancies were best explained by low ‘coverage’ in low ‘detec-
tion rate’ events (see Materials and Methods and Supplementary
Material, Table S2 online for further details).
We have classified these alternative splicing events into six
basic structural biotypes: cassettes, multicassettes, splice
donor shifts, splice acceptor shifts, terminal modifications and
intronizations (Fig. 2). Splice donor shifts include the alternative
use of proximal and distal sites at all BRCA1 tandem acceptor
(NAGNAG) sites (43), with the single notable exception of
exon 6. The latter is probably explained by the local sequence
context, as suggested by dedicated in silico analysis (see Supple-
mentary Material, Fig. S4 for further details). Some splicing
events are best described as mixed biotypes (Fig. 2 and
Table 4). Most annotated events classify into (multi)-cassette
biotypes (N ¼ 37), including two inclusion events that introduce
intron 3 and intron 13 genomic sequences into mature transcripts
(Table 1). The former corresponds to the genomic sequence ori-
ginally reported as BRCA1 exon 4 (13), and later considered an
intronic Alu element (27).
Functional annotation classifies BRCA1 splicing events into:
23 PTC-NMDs (splicing events introducing PTCs predicted to
Figure 1.Workflow. We display the workflow of the four-stage study conducted by ENIGMA investigators in order to elucidate the complexity of alternative splicing
at the BRCA1 locus. Key findings have been incorporated into the figure. Note that two novel splicing events detected by ENIGMA contributors in Stage 1 were not
validated in Stage 2 and have not been incorporated into the final list of 63 BRCA1 alternative splicing events. CE, capillary electrophoresis.
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Table 1. BRCA1 alternative splicing events (cassette biotype)
Designation RNAa Statusb Functional
annotationc
CDSa Breastd QAe Previously described?f
GENCODEg Bloodh Othersi
D2 r.-19_80del Cloned Non-Coding – Yes Minor – – BCCL
(20)
D3 r.81_134del Cloned PTC-NMDj – Yes Minor 006 LEU (17), PBMC
(17,20,39)
BCCL
(20)
P4 r.134_135ins135–4047_135–
3932
dir seq PTC-NMD – Yes Minor 002 – NP (13)
D5 r.135 _212del Cloned/
dir seq
No FS p.Phe46_Arg71del Yes Predominant 004 LEU (13,17,25,40),
LCLs(29)
NB (13)
D9 r.548_593del dir seq PTC-NMD – Yes Minor – LEU (17), PBMC (22) –
D10 r.594_670del Cloned PTC-NMD – Yes Minor – LEU (17) BCCL
(20)
D11 r.671_4096del Cloned No FS p.Ala224_Leu1365del Yes Minor 204 PBLs (41) –
D13 r.4186_4357del Cloned PTC-NMD – – Minor – – –
P13A r.4357_4358ins4358–
2785_4358–2719
Cloned No FS p.Lys1452_Ala1453ins22 Yes Minor 005 LCLs (19,35) NB (19)
D14 r.4358_c.4484del Imputed PTC-NMD – – Minor – – –
D15 r.4485_4675del Cloned PTC-NMD – – Minor – LEU (17) –
D17 r.4987_5074del Cloned PTC-NMD – – Minor – LEU (17) –
D18 r.5075_5152del dir seq No FS p.Asp1692_Trp1718delinsGly – Minor – – –
D20 r.5194_5277del Imputed No FS p.His1732_Lys1759del Yes Minor – – –
D21 r.5278_5332del Cloned PTC-NMD – Yes Minor – LEU (17) –
D22 r.5333_5406del Cloned FS-alternative
STOP
p.Asp1778_Thr1802fs∗32 Yes Minor 007 – –
D23 r.5407_5467del Cloned/dir
seq
FS-alternative
STOP
p.Gly1803_Ala1823delfs∗11 Yes Minor – – –
aAccording to HGVS guidelines (http://www.hgversusorg/mutnomen) last accessed December 2013. Nucleotide +1 corresponding to the A of the AUG translation initiation codon in the Ensemble reference
transcript ENST00000357654. Ensemble reference protein ENSP00000350283.
bEvents have been cloned and sequenced (cloned), directly sequenced from splicing assays (dir seq.) or imputed (see Materials and Methods).
cAccording to Mudge et al. (4) (see Materials and Methods for further details).
dDetected in normal breast tissue.
eQualitative abundance (QA) based on visual inspection of splicing assays (see Materials and Methods for further details).
fWe have excluded splicing events described as the outcome of germline mutation (i.e. for instance, D18 has been described previously as the outcome of various germline pathogenic mutations).
gGENCODE transcript IDs retrieved from Ensemble (if the corresponding splicing events is present in more than one transcript, the lowest ID number is shown).
hLEUs, PBMCs, PBLs, LCLs.
iBreast cancer cell lines (BCCLs), non-malignant placenta (NP). Non-malignant breast (NB).
jIn-frame event generating a PTC at the splice junction.
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Table 2. BRCA1 alternative splicing events (multicassette biotype)
Designation RNAa Statusb Functional annotationc CDSa Breastd QAe Previously described?f
GENCODEg Bloodh Othersi
D2,3 r.-19_134del Impute Non-Coding – Yes Minor – –
D2_5 r.-19_217del Impute Non-Coding – Yes Minor – –
D2_10 r.-19_670del dir seq. Non-Coding – – Minor 003 LCLs (24) NB (24)
D8,9 r.442_593del Impute PTC-NMD – – Minor – –
D8_10 r.442_670del Impute PTC-NMD – Yes Minor – –
D9,10 r.548_670del Cloned/dir seq No FS p.Gly183_Lys223del Yes Predominant 015 LEU (13,26),LCLs (29,42) NB,NO, (13) BCCL (20)
D9_11 r.548_4096del Cloned/dir seq No FS p.Ser184_Gly1366del Yes Predominant 203 LEU (17), LCL (24) NB (13)
D9_12 r.548_4185del Cloned PTC-NMD – Yes Minor – –
D10,11 r.594_4096del dir seq. PTC-NMD – Yes Minor – –
D10_12 r.594_4185del Cloned PTC-NMD – Yes Minor
D11,12 r.671_4185del Impute PTC-NMD – Yes Minor – –
D14_15 r.4358_4675del Cloned No FS p.Ala1453_Leu1558del – Minor – –
D14_17 r.4358_5074del Cloned No FS p.Ala1453_Thr1691del – Minor 202 LCLs (24) NB (24)
D14_18 r.4358_5152del Cloned No FS p.Ala1453_Trp1718delinsGly – Minor 205 LCLs (24) NB (24)
D14_19 r.4358_5196del Cloned PTC-NMD – – Minor – –
D15_17 r.4485_5074del Cloned PTC-NMD – Yes Minor – LEU (17), LCL (24) NB (24)
D15_19 r.4485_5193del Cloned PTC-NMD – Yes Minor – –
D21,22 r.5278_5406del Impute No FS p.Ile1760_Thr1802del Yes Minor – –
D21_23 r.5278_5467del Cloned FS-alternative STOP p.Ile1760_Ala1823delfs∗11 Yes Minor – –
D22,23 r.5333_5467del Impute FS-alternative STOP p.Asp1778_Ala1823delfs∗11 Yes Minor – –
aAccording to HGVS guidelines (http://www.hgversusorg/mutnomen) last accessed December 2013. Nucleotide +1 corresponding to the A of the AUG translation initiation codon in the Ensemble reference
transcript ENST00000357654. Ensemble reference protein ENSP00000350283.
bEvents have been cloned and sequenced (cloned), directly sequenced from splicing assays (dir seq.) or imputed (see Materials and Methods).
cAccording to Mudge et al. (4) (see Materials and Methods for further details).
dDetected in normal breast tissue.
eQualitative abundance (QA) based on visual inspection of splicing assays (see Materials and Methods for further details).
fWe have excluded splicing events described as the outcome of germline mutation (i.e. for instance, D18 has been described previously as the outcome of various germline pathogenic mutations).
gGENCODE transcript IDs retrieved from Ensemble (if the corresponding splicing events is present in more than one transcript, the lowest ID number is shown).
hLEUs, PBMCs, PBLs, LCLs.
iBreast cancer cell lines (BCCLs), non-malignant ovarian (NO) and non-malignant breast (NB).
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Table 3. BRCA1 alternative splicing events (miscellaneous biotypes)
Designation RNAa Statusb Functional annotationc CDSa Breastd QAe Previously described?f
GENCODEg Bloodh Othersi
Splice acceptor shift
D2p r.-19_-7del dir seq. UTR – Yes Minor – –
D8p r.442_444del Cloned/
dir seq
No FS p.Gln148del Yes Predominant 009 PBMC (13,20,29) NB, NO (13)
D13p r.4186_4188del Cloned/
dir seq
No FS p.Gln1396del Yes Predominant – LCLs (29)
D14p r.4358_4360del Cloned/
dir seq
No FS p.Ala1453del Yes Predominant 005 PBMC (13), LCLs (29) NB (13)
Splice donor shifts
D1Aq r.-25_-20del Cloned/
dir seq
UTR – Yes Predominant 006 LCLs (21) BCCL (20), BT (21)
P1aA r.-20_-19ins-20 + 1_-20 + 89 Cloned UTR – Yes Minor 010 –
D5q r.191_212del Cloned/
dir seq
PTC-NMD – Yes Predominant 010 PBMC (39), LEU (25),
LCL (29)
D11q r.788_4096del Cloned/
dir seq
No FS p.Ser264_Gly1366del Yes Predominant 007 LCLs (24) BCCL (20), NB (24)
Intronization
11D3110 r.788_3897del dir seq. PTC-NMD – – Minor – –
11D3240 r.788_4027del dir seq. No FS p.Gly263_Ser1342del – Minor – –
Terminal modification
(1B) dir seq UTR – Yes – – – BCCL,BT,OT,NB (23)
(IRIS) dir seq IntronicSTOP + polyA Not
tested
– 012 LCLs (18) BCCL, BT (18)
aAccording to HGVS guidelines (http://www.hgversusorg/mutnomen) last accessed December 2013. Nucleotide +1 corresponding to the A of the AUG translation initiation codon in the Ensemble reference
transcript ENST00000357654. Ensemble reference protein ENSP00000350283.
bEvents have been cloned and sequenced (cloned), directly sequenced from splicing assays (dir seq.) or imputed (see Materials and Methods).
cAccording to Mudge et al. (4) (see Materials and Methods for further details).
dDetected in normal breast tissue.
eQualitative abundance (QA) based on visual inspection of splicing assays (see Materials and Methods for further details).
fWe have excluded splicing events described as the outcome of germline mutation (i.e. for instance, D18 has been described previously as the outcome of various germline pathogenic mutations).
gGENCODE transcript IDs retrieved from Ensemble (if the corresponding splicing events is present in more than one transcript, the lowest ID number is shown).
hLEUs, PBMCs, PBLs and LCLs.
iBreast cancer cell lines (BCCLs), non-malignant breast (NB), non-malignant ovarian (NO), breast tumor (BT) and ovarian tumor (OT).
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Table 4. BRCA1 alternative splicing events (mixed biotypes)
Designation RNAa Statusb Functional annotationc CDSa Breastd QAe Previously described?f
GENCODEg Blood Others
Splice donor shift + (multi)-cassette
D1Aq,2 r.-25_80del dir seq Non-coding – Yes Minor – – –
D1Aq_3 r.-25_134del Imputed Non-coding – Yes Minor – – –
D1Aq_5 r.-25_217del Imputed Non-coding – Yes Minor – – –
D1Aq_10 r.-25_670del dir seq Non-coding – Yes Minor – – –
(Multi)-cassette + splice acceptor shift
D10_13p r.594_4188del Imputed PTC-NMD – Yes Minor – – –
D11_13p r.671_4188del Imputed PTC-NMD – Yes Minor – –
D13_14p r.4186_4360del Imputed PTC-NMD – – Minor – – –
P13A,D14p r.4357_4358ins4358–2785_4358–2719 + r.4358_4360del Imputed No FS p.Ala1453delins22 Yes Minor 005 – –
Terminal modification + (multi)-cassette
(1B),D2 r.-19_80del dir seq Non-coding – Yes – 206 – –
(1B),D2,3 r.-19_134del dir seq Non-coding – Yes – – – –
(1B),D2_5 r.-19_217del Imputed Non-coding – – – – – –
Multicassette + cassette
D2,3,P4 r.-19_134del+r.134_135ins135–4047_135–3932 Imputed Non-coding – – Minor – – –
Splice donor shift + splice acceptor shift
D1Aq,D2p r.-25_-7del cloned UTR – Yes Minor – – –
Splice donor shift + multicassette + cassette
D1Aq_3,P4 r.-25_134del + r.134_135ins135–4047_135–3932 cloned Non-coding – – Minor – – –
aAccording to HGVS guidelines (http://www.hgversusorg/mutnomen) last accessed December 2013. Nucleotide +1 corresponding to the A of the AUG translation initiation codon in the Ensemble reference
transcript ENST00000357654. Ensemble reference protein ENSP00000350283.
bEvents have been cloned and sequenced (cloned), directly sequenced from splicing assays (dir seq.) or imputed (see Materials and Methods).
cAccording to Mudge et al. (4) (see Materials and Methods for further details).
dDetected in normal breast tissue.
eQualitative abundance (QA) based on visual inspection of splicing assays (see Materials and Methods for further details).
fWe have excluded splicing events described as the outcome of germline mutation (i.e. for instance, D18 has been described previously as the outcome of various germline pathogenic mutations).
gGENCODE transcript IDs retrieved from Ensemble (if the corresponding splicing events is present in more than one transcript, the lowest ID number is shown).
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induce the Nonsense-Mediated RNA Decay pathway), 15
in-frames (ranging from subtle effects at NAGNAG sites to
large deletions removing more than 50% of the reference
CDS), 13 non-coding (eliminating the full-length start codon),
5 UTRs (splicing events modifying UnTranslated regions), 4
frame-shifts generating PTCs not predicted to induce NMD
Figure 2.Splicing structural biotypes identified in the present study. For the sake of clarity, the figure represents conceptual schemes of splicing structural biotypes, not a
description of theBRCA1 locus itself. Exonic sequencesare indicated byblack boxes. Intronic sequences bygray lines (or boxes ifexonic in the reference splicingpattern).
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(PTCs located in exon 24) and 1 internal PTC with polyadenyla-
tion (IRIS) (Tables 1–4).
Splicing ‘assays’ were developed to detect BRCA1 splicing
events, not to address quantitative aspects. Yet, visual inspection
allowed us to identify 10 ‘predominant BRCA1’ splicing events:
D1Aq, D5, D5q, D8p, D9, D(9,10), D9_11, D11q, D13p and
D14p, eight of which were later analyzed (Stage 4) by semi-
quantitative CE (not feasible in the case of D9_11 and D11q,
see Materials and Methods for further details).
We performed a comprehensive screening of BRCA1 alterna-
tive splicing events in one healthy breast tissue sample
(BREAST). Remarkably, most splicing events previously iden-
tified in blood samples (43 out of 63) were detected, despite the
lower ‘coverage’. Those not detected tended to be low ‘detection
rate’ events in blood derived samples (see Supplementary Mater-
ial, Table S2 for further details). Equally relevant, our analysis
did not identify any splicing events that had not been detected
previously in blood. Visual inspection of saturating PCR
assays detected the very same 10 ‘predominant’ splicing
events previously identified in blood-related samples.
Semi-quantitative CE indicated obvious differences among
‘predominant’ events both in blood and breast tissue (Fig. 3).
While some events represented roughly 5% of the full-length
signal (D5, D5q, D9, D13p), others represented up to 30%
(D8p, D(9,10), D14p). Finally, we observed similar levels of
D1Aq and full-length transcripts. Very similar splicing patterns
were observed when analyzing LEU, PBMC, PBL and LCL
samples separately (see Supplementary Material, Figs S5–
S12). Although semi-quantitative profiling of allBRCA1 splicing
events described here is beyond the scope of the present study,
there are some notable observations in relation with Stage 2 ‘de-
tection rate’ (Supplementary Material, Table S2). The average
‘detection rate’ of Stage 2 splicing events is 46%, but there is a
clear distinction between the average ‘detection rates’ of ‘pre-
dominant’ versus ‘minor’ events (86 versus 39%). Furthermore,
the ‘detection’ rate reaches 100% in four ‘predominant’ events
representing ≥30% of the full-length signal (D1Aq, D8p,
D(9,10), D14p), but decreases to 72% (range 62–87%) for
those representing only 5% of the full-length signal (D5, D5q,
D9, D13p). Taken together, these observations suggest that, in
ourexperimental setting, the ‘detection rate’ of an individual spli-
cing event (Supplementary Material, Table S2) is related with the
actual expression level of that particular event.
Interestingly, CE analysis allowed us to identify peaks
imputed to transcripts combining two or more independent spli-
cing events. For instance, 7–11q assays (Supplementary Mater-
ial, Fig. S1A) demonstrated the existence of RNA species
combining D8p with D9, D10 and D(9,10) events. Similarly,
12–14 assays (Supplementary Material, Fig. S1B) demonstrated
the existence of RNA species containing D13,P13A, D13p and
D14p events in almost all possible combinations, with the only
exception being that RNA species combining D13 with P13A
were not observed. Further supporting this scenario, the analysis
of 7–12 assays revealed a high diversity of transcripts combin-
ing D8p, D9, D10, D(9,10), D11 and D11q splicing events (Sup-
plementary Material, Fig. S3), including the detection of
transcripts combining D(9,10) with D11q. The latter, for the
sake of consistence annotated as (D9,10 + D11q) in Supplemen-
tary Material, Figure S3, but often referred to as D(9,10,11q) in
the literature, is one of few BRCA1 splicing isoforms described
previously as predominant (16). ‘Detection rate’ of (D9,10 +
D11q) reached 100% in Stage 2 (data not shown), further sup-
porting a link between ‘detection rate’ and actual expression
level.
Note that, overall, the CE signal corresponding to transcripts
containing multiple splicing events is consistently lower than
that of the transcripts containing the corresponding individual
events, as expected from a random combination of independent
elements (see several examples in Supplementary Material, Figs
S1 and S3).
DISCUSSION
We have combined reverse transcription polymerase chain reac-
tion (RT-PCR), CE, cloning and conventional sequencing to de-
scribe naturally occurring BRCA1 alternative splicing with
unprecedented resolution. To our knowledge, 34 out of the 63
splicing events reported here are novel findings, whereas only
22 events have been described previously in blood samples (see
Tables 1–4 for further details). However, we have not been
able to validate up to eight BRCA1 splicing events previously
reported by others (including two Stage 1 events reported by con-
tributors of the present manuscript). While it is likely that some of
these events do not qualify for ‘naturally occurring’ events, the
data suggest that characterizing the full complexity of BRCA1
splicing will require further studies (see Supplementary Material,
Table S3 for further details). This is also suggested by the fact that
we have identified several signals compatible with additional
splicing events that, nonetheless, we have not been able to anno-
tate (see Supplementary Material, Figs S1 and S3).
Overall, our data indicate that most naturally occurringBRCA1
splicing events are rather minor if compared with the full-length
signal. However, we have identified 10 ‘predominant’ splicing
events that appear to represent a substantial fraction of the
full-length expression using semi-quantitative measures. Not
surprisingly, all 10 ‘predominant’ events have been described
previously. Indeed, six of them (D5, D5q, D8p, D(9,10), D13p
and D14p) have been described recently as BRCA1 splicing
events ‘consistently found in control samples’ (29).
Genome-wide analyses suggest that cassette events (30–50%
of all splicing events) are the commonest alternative splicing
structural biotypes observed in mammals (4,5,10). In this
regard, the human BRCA1 gene can be described as typical,
since 37 out of the 63 (58%) splicing events here reported are cas-
sette like. Remarkably, allBRCA1 internal exons are involved in
one or more cassette events so that, formally speaking, BRCA1
lacks constitutive exons. Yet, with few exceptions (D5, D9,
D(9,10), D9_11) cassette events are rather “minor events”, so
that most internal exons are best described as ‘quasi-constitutive
exons’. The number of splice site shifts (N ¼ 9) is much lower,
but 6 out of 10 “predominant” events correspond to this
biotype. Remarkably, we have not identified structural biotypes
such as mutually exclusive cassette exons or retained introns
(5,10). Yet, we have identified two intronization events
(Fig. 2). This would appear to be a rare structural biotype,
since it is not included in a comprehensive catalog of structural
biotypes (68 different biotypes) identified in human, mouse
and several non-mammal vertebrates (4). Perhaps, intronization
events occurring in vertebrates are associated with exceptionally
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long exons, such as human BRCA1 exon 11 (3426 bp versus an
average exon length of 180 bp in the human genome).
The spectrum of possible splicing events occurring at a single
locus is so wide that any attempt to catalog it will inevitably be
biased by the analytical approach employed. In our experience,
CE analysis of RT-PCR products is very sensitive for detecting
minor events, subtle size-effects and multicassette events (37).
However, minor events involving long (≥1000 bp) intron reten-
tions (if any) will usually escape detection, as expected product
sizes are out of range of CE. Furthermore, our analytical ap-
proach does not allow discovery of novel terminal events
which are not formally splicing events, but are nonetheless
reported as major contributors to exon variability in mRNAs
(3,5). In this regard, we have limited our study to analyze the
expression of two previously reported terminal events
(Exon1B and IRIS) by dedicated assays.
We have shown previously that semi-quantitative CE is able to
detect splicing quantitative trait loci (sQTLs) such as rs1799965,
a rare SNP [minor allele frequency (MAF), 0.001] that is asso-
ciated with an increase in expression of BRCA1 D9,10 (26), and
rs9534262, a common SNP (MAF. 0.40) associated with an in-
crease in BRCA2 D17,18 (44). In the present study, we have not
been able to detect interindividual variability, suggesting that this
is below technical replica variability. Since we have analyzed alter-
native splicing in a relative large number of control samples (N¼
48), our data suggest that common sQTLs at the BRCA1 gene (if
any) are likely to induce more subtle effects than those reported
for rs1799965 (c.591C. T) and rs9534262 (c.7806–14T. C).
Figure 3.BRCA1 splicing events in blood and breast tissues. (A) The boxplots (low, Q1, median, Q3 and high values are displayed) show the expression level of eight
predominant BRCA1 alternative splicing events relative to the full length. Relative expression level was measured by semi-quantitative CE (see Materials and
Methods). BLOOD displays LEUs, PBMCs, PBMCs and LCLs data pooled together (different control samples plus technical replicates). N indicates the number
of individual data points (different control samples plus technical replicates). BREAST displays data from one BREAST sample. In this case, N equals the
number of technical replicates performed. Normal outliers (.1.5 inter quartile range, IQR) display a small circle. Extreme outliers (.3 IQR) display an asterisk.
(B) Representative examples of 7–11q CE assays performed with four different RNA sources. Overall, the analysis suggests that BRCA1 alternative splicing is
similar, regardless of the RNA source analyzed. Differences are restricted to the presence/absence of ‘minor’ events. More important, replica experiments show
that differences are not RNA source (or sample) specific, but rather the results of stochastic preferential amplification of ‘minor’ isoforms. Peaks representing a com-
bination of two independent splicing events (SE) are annotated as (SE1 + SE2).
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It is important to point out that we have produced a catalog of
alternative splicing events, which may not represent a catalog of
RNA isoforms (we have not cloned individual mRNAs). At
present, we cannot rule out the possibility that certain splicing
events tend to occur together (linked splicing model), so that the
actual number of BRCA1 mRNA isoforms might be lower than
the number of splicing events reported here. Yet, overall our data
favor an unlinked splicing model in which most, if not all, non-
mutually exclusive alternative splicing events are randomly
combined into individual mRNA molecules to potentially
produce hundreds of different BRCA1 isoforms. According to
GENCODE v7, human protein-coding loci express on average
6.31 alternatively spliced transcripts (10), and those loci with
.20 annotated isoforms are very rare (3). Therefore, our analysis
raises the interesting possibility of BRCA1 being a locus with par-
ticularly high levels of alternative splicing. However, global esti-
mations of alternative splicing levels are based on genome-wide
RNA-seq efforts that may underestimate the true level of alterna-
tive splicing. At least, this is supported by targeted RNA-seq
experiments that identify hundreds of previously unannotated
isoforms in even extensively studied protein-coding loci such as
TP53 and HOX (45). If proven true, the finding that BRCA1 is a
locus with a high level of alternative splicing would be consistent
with recent genome-wide analyses connecting high-level alterna-
tive splicing loci with intrinsically disordered proteins/domains
(IDPs/IDDs), IDPs/IDDs with Hub proteins and Hub proteins
with disease (46–49). TP53 represents a paradigm of this associ-
ation (45,47,48). Similar to TP53, BRCA1 is a disease associated
genetic locus coding for an IDP/IDD protein with Hub properties
(47). Accordingly, high-level alternative splicing would indeed
be an expected feature of the BRCA1 locus. Remarkably, CE
splicing analysis at the BRCA2 locus (a gene fairly similar to
BRCA1 in terms of overall size and exon/intron structure, but
coding for a protein that lacks IDDs and/or Hub features) reveals
a much lower extent of alternative splicing (ENIGMA consortium
internal data).
Regardless of its biological significance, we believe that the
comprehensive description of BRCA1 alternative splicing
reported here will be highly relevant for diagnosis, in particular
when assessing the impact of BRCA1 germline variants on spli-
cing. Recently, the ENIGMA consortium conducted a multicen-
tre investigation aimed at comparing in vitro splicing assay
protocols and elaborating best practice guidelines (37). The
study addressed analytical aspects such as primers design,
reverse transcriptase protocols, NMD inhibition and detection
methods, and identified primers design (positioning primers)
as a major source of variability across laboratories. The study
concluded that a prior knowledge of the expected transcripts
(naturally occurring alternative splicing isoforms) was a key
factor for proper primers design and clinical assessment (37).
Previous studies have identified as well alternative splicing as
a critical aspect to be considered in the design and analysis of
BRCA1 in vitro splicing assays (26). In this regard, the catalog
of splicing events here identified will be a valuable tool to
improve the design (primers can be strategically positioned to
include or exclude specific splicing events in function of the pos-
ition of the variants under scrutiny) and analysis (at both qualita-
tive and quantitative level) of future BRCA1 in vitro splicing
assays, thus improving the clinical interpretation of the out-
comes. In turn, this will facilitate the integration of BRCA1
in vitro splicing assays into the multifactorial likelihood
models that are developed by the ENIGMA consortium to
assess the clinical relevance of genetic variants (38).
Despite its comprehensiveness, the abovementioned
ENIGMA study comparing in vitro splicing assays protocols
was conducted in RNAs isolated from LCLs, so that did not
evaluate the impact of using other blood-related RNA sources.
Yet, LEUs or PBLs are common RNA sources for in vitro spli-
cing assays in genetic testing laboratories worldwide (15). In
the present study, we have shown that BRCA1 alternative spli-
cing is similar in four different blood RNA sources (LEUs,
PBLs, PBMCs and LCLs), suggesting that the actual blood-
related RNA source used for assessing the role of BRCA1
germline variants on splicing is unlikely to represent a major
contributor to variability of results. Further on, our data
suggest that BRCA1 alternative splicing is similar in blood and
breast tissues, supporting that in vitro splicing assays performed
in blood are relevant for diagnosis.
Although the biological relevance of BRCA1 alternative spli-
cing is largely unknown, the precise knowledge of the different
splicing events will be instrumental for the definition of its func-
tional (and clinical) relevance. Individual BRCA1 mRNA iso-
forms can be monitored more closely in future splicing assays
(preferably including accurate quantification), and the function-
al relevance of their putatively encoded proteins can be further
evaluated by in vitro transfection of the corresponding cDNA
constructs to rescue gene expression, as recently shown for
BRCA1 missense variants (50), and two BRCA1 alternative
splicing isoforms (17,51).
Finally, we believe that CE scanning, as here conducted for
BRCA1 analysis, is a feasible approach to develop accurate
catalogs of locus-specific alternative splicing events that can
assist the analysis and validation of data from targeted
RNAseq experiments.
MATERIALS AND METHODS
Samples
We have analyzed BRCA1 alternative splicing in RNA samples
from healthy control individuals. RNA was isolated from whole
blood LEUs, ficoll-isolated PBMCs, primary cultures of stimu-
lated PBLs and LCLs. In addition, RNA was isolated from an
epithelial enriched area of one healthy breast tissue obtained
after cosmetic surgery (BREAST). In Stage 1 (see workflow in
Fig. 1) different contributing laboratories used different isola-
tion protocols and/or cDNA synthesis strategies, as described
in a recent ENIGMA paper (37). A full description of RNA iso-
lation and cDNA synthesis protocols used in Stages 2 and 3 (see
workflow in Fig. 1) is provided in Supplementary methods. The
study was approved by the Institutional Review Board of each
participating center.
Identification, validation and relative quantification of
‘naturally occurring’ BRCA1 alternative splicing events
For the purpose of this study, we define alternative splicing
events as those incorporating splice junctions not present in
the reference transcript Ensemble ENST00000357654 (here-
after referred as full-length transcript). The only exception is
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BRCA1-IRIS (see Introduction), a locus product for which no
specific splice junction exists (18). Multiple combinations of
forward and reverse primers located at exonic regions (as
defined by the full-length transcript) were used to amplify
cDNAs. A PCR performed with a particular combination of
primers will be referred throughout the text as aBRCA1 splicing
‘assay’. We conducted a four-stage project as follows (see work-
flow in Fig. 1).
In Stage 1, contributing centers used their own control
samples (blood related) and ‘assays’ to identify alternative spli-
cing events at theBRCA1 gene. All Stage 1 primers are available
upon request. At this stage, splicing ‘assays’ were analyzed by
EtBr stained agarose gel electrophoresis, CE and/or direct se-
quencing, depending on the contributing center. Both confirmed
(sequenced) and predicted (size-matching) events were consid-
ered. In addition, we performed a comprehensive review of the
literature in order to identify allBRCA1 splicing events previous-
ly described, including ‘naturally occurring’ events, but also
splicing events not formally validated as such (like those
solely detected in tumor samples and/or cell lines). Stage 1 ex-
perimental and review data were pooled together to elaborate a
working list of 42 BRCA1 alternative splicing events (see Sup-
plementary Material, Table S1).
In Stage 2, Stage 1 information was used to develop a panel of
18 overlapping ‘assays’ (all primer sequences are provided as
Supplementary Material) that allowed a comprehensive scan-
ning of BRCA1 splicing events by CE (see Supplementary Ma-
terial, Figs S1–S3 and Table S1). Thermal cycling consisted
of an initial 10-min hold at 958C, followed by 30-s hold at
958C, 30-s hold at 588C and 30-s hold at 728C (increased to
2 min for exon11 containing assays) for 45 cycles to maximize
sensitivity. Stage 2 screening was performed in 48 healthy
control samples of European ancestry, including 10 LEUs, 8
PBMCs, 20 PBLs and 10 LCLs. Several centers contributed
samples at this stage, but actual screening was centralized in
one laboratory. CE analyses were performed in a 3130 Genetic
Analyzer (Applied Biosystems) with GeneScan 500/1200 Size
Standards (Applied Biosystems) as internal markers. Size-
calling was performed with GeneMapper v4.0 Software
(Applied Biosystems). Some splicing events were captured by
one ‘assay’, while others were captured by two or more overlap-
ping ‘assays’ (Supplementary Material, Table S1). Stage 2 cen-
tralized screening involved a total of 4281 CE data points (one
data point defined as each technical replica of an individual spli-
cing event assayed in one sample). ‘Coverage’ (defined here as
data points per splicing event) ranged from 18× to 163×
(67× on average). ‘Detection Rate’ (% of positive data points)
ranged from 3 to 100%. By far, the highest ‘coverage’ was
obtained in PBLs samples, with 2055 data points (see Supple-
mentary Material, Table S2 for further details). None of the
‘assays’ listed in Supplementary Material, Table S1 allowed
BRCA1-IRIS detection. For that purpose, we developed a dedi-
cated assay that does not rely on CE analysis (see Supplementary
Material). Stage 2 allowed us not only to validate 34 out of 42
Stage 1 events in a cohort of control samples but also to validate
29 additional splicing events. For the purpose of this study, we
have validated findings only if sequenced, or imputed by two
or more contributing centers with different primer sets.
Visual inspection of CE assays (or EtBr agarose stained gels in
the case of exon 11 containing assays) revealed that most
splicing events were easily classified into two categories accord-
ing to their signal relative to the full-length transcript, hereafter
refereed as ‘predominant’ and ‘minor’ events. BRCA1-IRIS and
exon1B transcripts were not classifiable because the full-length
reference transcript was not co-amplified in the corresponding
assays. Later, splicing events classified as ‘predominant’ were
further characterized by semi-quantitative CE assays (see
below).
In Stage 3, screening ofBRCA1 splicing events was performed
in one normal breast sample (BREAST). ‘Assays’ and CE proto-
cols were as in Stage 2, although ‘coverage’ was much lower (see
Supplementary Material, Table S2).
Finally, in Stage 4 we investigated the expression level rela-
tive to the full length in eight alternative splicing events previ-
ously annotated as ‘predominant’. With this aim, LEUs,
PBMCs, PBLs, LCLs and BREAST samples were reanalyzed
with four splicing ‘assays’ (E1–E6, E7–E11q, E12–E13 and
E12–E14) performed in semi-quantitative (33 PCR cycles) con-
ditions (semi-quantitative CE). Relative quantification of indi-
vidual splicing events was expressed as the average ratio
between the peak area of that particular event and the peak
area of the full-length signal (Fig. 3 and Supplementary Material,
Figs S5–S12). Semi-quantitative CE analysis of two ‘predomin-
ant’ events (D9_11 and D11q) was not feasible because of the
large-size difference (.3300 bp) between spliced and full-
length products.
Splicing events designation
We have designatedBRCA1 exons following the Breast Core In-
formative database nomenclature (52), so that the 22 coding
exons of the reference full-length transcript are numbered
from 2 to 24 with no exon 4 defined (13). We have designated
splicing events combining the following symbols:D (skipping),
P (retention), p (proximal) and q (distal). In addition, we have
also used non-systematic designations previously established
in the scientific literature, including IRIS, exon1A, exon1aA,
exon1B, exon4 and exon13A (13,18,19,22,23).
Splice junction sequencing
Depending on the particular splicing event investigated (and/or
contributing center), different approaches were followed. Direct
sequencing of individual ‘assays’ (sometimes with internal
primers at selected locations) allowed us to sequence 25
events; including ‘predominant’ and ‘minor’ events (see
Tables 1–4). The latter was possible thanks to stochastic prefer-
ential amplification of ‘minor’ events observed in 45-cycle
RT-PCR assays (an illustrative example is shown in Supplemen-
tary Material, Fig. S2). Alternatively, agarose or polyacrylamide
gel excised splicing assay products were cloned into the
pGEM-T vector (Promega) and sequenced. Cloning allowed
us to sequence 32 events (see Tables 1–4). All sequence
reactions were performed using the ABI PRISMw BigDyeTM
Terminator Cycle Sequencing kit (Applied Biosystems)
and examined with an ABI 3130 Genetic Analyzer (Applied
Biosystems), using the Sequencing Analysis software (Applied
Biosystems).
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Imputation of splicing events
For this purpose, we elaborated alternative splicing models that
best explained the peak pattern observed in CE analyses. Impu-
tations were performed combining CE size-calling data, sequen-
cing findings and GENCODE annotations retrieved through the
Ensemble Genome Browser (http://www.ensembl.org, last
accessed December 2013). As a rule, we imputed splicing
events only if compatible with the use of canonical splice sites
(GT-AG) present in the BRCA1 reference genomic sequence
GRCh37:17:41195712:41322890:-1 (http://www.ensembl.org,
last accessed December 2013). The approach allowed us to anno-
tate BRCA1 splicing events not supported by direct sequencing
evidence (referred throughout the text as imputed events). Im-
putation was also used to deduce the existence of transcripts
combining multiple splicing events. Two representative exam-
ples of BRCA1 splicing models are shown in Supplementary
Material, Figure S1.
Structural and functional annotation of alternative
splicing events
Structural and functional annotation has been performed as in
Mudge et al. (4), although we incorporated an additional struc-
tural biotype referred throughout the text as intronization. First
described in Caenorhabditis species (53), intronization refers
to the conversion of a single exon into two exons and one inter-
vening intron (see Fig. 2). Functional annotation ofBRCA1 spli-
cing events includes ‘non-coding’ (splicing events eliminating
the full-length start codon), ‘PTC-NMDs’ (splicing events intro-
ducing PTCs predicted to induce the nonsense-mediated
RNA decay pathway), ‘No-FS’ (in-frame splicing events),
‘FS-alternative STOP’ (frame-shift events generating PTCs
not predicted to induce NMD as they are located in the most
downstream BRCA1 exon), ‘UTRs’ (splicing events modifying
UnTranslated regions) and one internal PTC with polyadenyla-
tion (IRIS).
Identification of BRCA1 alternative splicing events
in public domain databases
Studies published up to June 2013 that contained data from
BRCA1 splicing assays were identified by carrying out literature
searches using the LOVD database (http://chromium.liacs.nl/
LOVD2/cancer/home), PubMed (http://www.ncbi.nlm.nih.
gov/pubmed) and Google Scholar (http://scholar.google.com),
using the following keywords: BRCA1, BRCA2 and splicing.
Each report was reviewed in detail to extract the following
data: splicing events detected (excluding those directly attribu-
ted to germline pathogenic mutations) and RNA source. The
data, together with information retrieved from Ensembl
(BRCA1 transcripts), have been incorporated into Tables 1–4
and Supplementary Material, Tables S1 and S3.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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